ERBB2 and neoplasm: Our NGS cut-off for ERBB2 amplification is set at >4 copies (Minimum Ploidy Gain, 5% CI >4), and taking tumor contents and intratumoral heterogeneity into consideration, lowering the cut-off to ≥3 copies could potentially improve the concordance rate from 76.1% to 88.0%.